Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells.

Jiao J, Hindoyan A, Wang S, Tran LM, Goldstein AS, Lawson D, Chen D, Li Y, Guo C, Zhang B, Fazli L, Gleave M, Witte ON, Garraway IP, Wu H.

PLoS One. 2012;7(8):e42564. doi: 10.1371/journal.pone.0042564. Epub 2012 Aug 3.

2.

A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.

Sackmann Sala L, Boutillon F, Menara G, De Goyon-Pélard A, Leprévost M, Codzamanian J, Lister N, Pencik J, Clark A, Cagnard N, Bole-Feysot C, Moriggl R, Risbridger GP, Taylor RA, Kenner L, Guidotti JE, Goffin V.

J Pathol. 2017 Sep;243(1):51-64. doi: 10.1002/path.4924. Epub 2017 Jul 28.

PMID:
28603917
3.

Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model.

Mulholland DJ, Xin L, Morim A, Lawson D, Witte O, Wu H.

Cancer Res. 2009 Nov 15;69(22):8555-62. doi: 10.1158/0008-5472.CAN-08-4673. Epub 2009 Nov 3.

4.

Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten-/-TP53-/- prostate cancer model.

Abou-Kheir WG, Hynes PG, Martin PL, Pierce R, Kelly K.

Stem Cells. 2010 Dec;28(12):2129-40. doi: 10.1002/stem.538.

5.

Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice.

Lu TL, Huang YF, You LR, Chao NC, Su FY, Chang JL, Chen CM.

Am J Pathol. 2013 Mar;182(3):975-91. doi: 10.1016/j.ajpath.2012.11.025. Epub 2013 Jan 9.

PMID:
23313138
6.

Self-renewing Pten-/- TP53-/- protospheres produce metastatic adenocarcinoma cell lines with multipotent progenitor activity.

Abou-Kheir W, Hynes PG, Martin P, Yin JJ, Liu YN, Seng V, Lake R, Spurrier J, Kelly K.

PLoS One. 2011;6(10):e26112. doi: 10.1371/journal.pone.0026112. Epub 2011 Oct 11.

7.

Dependence of castration-resistant prostate cancer (CRPC) stem cells on CRPC-associated fibroblasts.

Adisetiyo H, Liang M, Liao CP, Jeong JH, Cohen MB, Roy-Burman P, Frenkel B.

J Cell Physiol. 2014 Sep;229(9):1170-6. doi: 10.1002/jcp.24546.

8.

Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer.

Chen X, Li Q, Liu X, Liu C, Liu R, Rycaj K, Zhang D, Liu B, Jeter C, Calhoun-Davis T, Lin K, Lu Y, Chao HP, Shen J, Tang DG.

Clin Cancer Res. 2016 Sep 1;22(17):4505-16. doi: 10.1158/1078-0432.CCR-15-2956. Epub 2016 Apr 8.

9.

CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines.

Muraro MG, Mele V, Däster S, Han J, Heberer M, Cesare Spagnoli G, Iezzi G.

Stem Cells Transl Med. 2012 Aug;1(8):592-603. doi: 10.5966/sctm.2012-0003. Epub 2012 Aug 6.

10.

Epcam, CD44, and CD49f distinguish sphere-forming human prostate basal cells from a subpopulation with predominant tubule initiation capability.

Guo C, Liu H, Zhang BH, Cadaneanu RM, Mayle AM, Garraway IP.

PLoS One. 2012;7(4):e34219. doi: 10.1371/journal.pone.0034219. Epub 2012 Apr 13.

11.

Single-Cell Analysis Identifies LY6D as a Marker Linking Castration-Resistant Prostate Luminal Cells to Prostate Progenitors and Cancer.

Barros-Silva JD, Linn DE, Steiner I, Guo G, Ali A, Pakula H, Ashton G, Peset I, Brown M, Clarke NW, Bronson RT, Yuan GC, Orkin SH, Li Z, Baena E.

Cell Rep. 2018 Dec 18;25(12):3504-3518.e6. doi: 10.1016/j.celrep.2018.11.069.

12.

Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines.

Seiler D, Zheng J, Liu G, Wang S, Yamashiro J, Reiter RE, Huang J, Zeng G.

Prostate. 2013 Sep;73(13):1378-90. doi: 10.1002/pros.22685. Epub 2013 May 31.

PMID:
23728788
13.

Early human prostate adenocarcinomas harbor androgen-independent cancer cells.

Fiñones RR, Yeargin J, Lee M, Kaur AP, Cheng C, Sun P, Wu C, Nguyen C, Wang-Rodriguez J, Meyer AN, Baird SM, Donoghue DJ, Haas M.

PLoS One. 2013 Sep 25;8(9):e74438. doi: 10.1371/journal.pone.0074438. eCollection 2013.

14.

Genomic analysis of prostate cancer stem cells isolated from a highly metastatic cell line.

Rowehl RA, Crawford H, Dufour A, Ju J, Botchkina GI.

Cancer Genomics Proteomics. 2008 Nov-Dec;5(6):301-10.

15.

TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation.

Casey OM, Fang L, Hynes PG, Abou-Kheir WG, Martin PL, Tillman HS, Petrovics G, Awwad HO, Ward Y, Lake R, Zhang L, Kelly K.

PLoS One. 2012;7(7):e41668. doi: 10.1371/journal.pone.0041668. Epub 2012 Jul 30.

16.

Nuclear receptor profiling in prostatospheroids and castration-resistant prostate cancer.

Wang Z, Wu D, Ng CF, Teoh JY, Yu S, Wang Y, Chan FL.

Endocr Relat Cancer. 2018 Jan;25(1):35-50. doi: 10.1530/ERC-17-0280. Epub 2017 Oct 17.

PMID:
29042395
17.

Plasma membrane proteomics of tumor spheres identify CD166 as a novel marker for cancer stem-like cells in head and neck squamous cell carcinoma.

Yan M, Yang X, Wang L, Clark D, Zuo H, Ye D, Chen W, Zhang P.

Mol Cell Proteomics. 2013 Nov;12(11):3271-84. doi: 10.1074/mcp.M112.025460. Epub 2013 Jul 31.

18.

PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.

Li Y, Su J, DingZhang X, Zhang J, Yoshimoto M, Liu S, Bijian K, Gupta A, Squire JA, Alaoui Jamali MA, Bismar TA.

J Pathol. 2011 May;224(1):90-100. doi: 10.1002/path.2855. Epub 2011 Mar 7.

PMID:
21381033
19.

Analysis of multiple markers for cancer stem-like cells in human thyroid carcinoma cell lines.

Shimamura M, Nagayama Y, Matsuse M, Yamashita S, Mitsutake N.

Endocr J. 2014;61(5):481-90. Epub 2014 Feb 15.

20.

CD49f-positive cell population efficiently enriches colon cancer-initiating cells.

Haraguchi N, Ishii H, Mimori K, Ohta K, Uemura M, Nishimura J, Hata T, Takemasa I, Mizushima T, Yamamoto H, Doki Y, Mori M.

Int J Oncol. 2013 Aug;43(2):425-30. doi: 10.3892/ijo.2013.1955. Epub 2013 May 24.

PMID:
23708747

Supplemental Content

Support Center